The effects of circulating GDF-15 on adverse outcomes in patients with HF or coronary artery disease have been meta-analyzed in three studies previously [10,11,12], but diabetic patients were a minority in each of those studies and none has specifically summarized the effects of elevated GDF-15 in patients with diabetes. This evidence concerns the gene GDF15 and hydrops fetalis.